Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 6/20 | 0.55 |
| ▸ | CCR3 | P51677 | 3/20 | 0.55 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.48 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.46 |
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
| ▸ | VNN1 | O95497 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | HRH2 | P25021 | 3/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1626059 | 0.83 | HRH1 (0.50) | HRH1CCR3HRH3TBXAS1HTR2C | |
| SCHEMBL3605627 | 0.81 | MET (0.52) | VNN1SLC6A4SLC6A2SLC6A3DRD2 | |
| SCHEMBL3289104 | 0.80 | HRH3 (0.68) | HRH1CCR3HRH3SLC6A4SLC6A2 | |
| Hydrochloric Acid SCHEMBL4227255 | 0.79 | HRH3 (0.67) | HRH1CCR3HRH3SLC6A4SLC6A2 | |
| SCHEMBL3423446 | 0.78 | MAOA (0.43) | HRH3DRD2DRD3ALDH1A1 | |
| SCHEMBL3601894 | 0.77 | DRD2 (0.50) | HRH1CCR3TBXAS1VNN1SLC6A4 | |
| SCHEMBL4443660 | 0.75 | HRH3 (0.60) | HRH1CCR3HRH3SLC6A4SLC6A2 | |
| SCHEMBL11466424 | 0.75 | CHRNB4 (0.55) | HRH1CCR3TBXAS1SLC6A4 | |
| SCHEMBL22835727 | 0.74 | MGLL (0.50) | HRH1CCR3 | |
| SCHEMBL7388461 | 0.73 | TBXAS1 (0.56) | HRH1CCR3TBXAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7723526-B2 | Benzoimidazole compounds | JANSSEN PHARMACEUTICA NV (BE) | 2010-05-25 | — | — | US | disclosed |
| US-7723527-B2 | Benzoimidazole compounds | JANSSEN PHARMACEUTICA NV (BE) | 2010-05-25 | — | — | US | disclosed |
| US-7723359-B2 | Benzoimidazole compounds | JANSSEN PHARMACEUTICA NV (BE) | 2010-05-25 | — | — | US | disclosed |
| US-7705149-B2 | Benzoimidazole compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-04-27 | — | — | US | disclosed |
| US-7705143-B2 | 5-Fluoro-4-methyl-2-{2-[4-(4-methyl-[1,4]diazepan-1-yl)-butoxy]-pyridin-4-yl}-1H-benzoimidazole; use in leukocyte recruitment inhibition, in modulating H4 receptor, and in treating conditions such as inflammation, H4 receptor-mediated conditions | JANSSEN PHARMACEUTICA N.V. (BG) | 2010-04-27 | — | — | US | disclosed |
| US-7662966-B2 | For example, 5-tert-Butyl-2-{2-[4-(1-methyl-piperidin-4-yl)-butoxy]-pyridin-4-yl}-1H-benzoimidazole; use in leukocyte recruitment inhibition, in modulating H4 receptor, and in treating conditions such as inflammation, H4 receptor-mediated conditions, and related conditions | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-02-16 | — | — | US | disclosed |
| US-20090281307-A1 | Benzoimidazole compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-11-12 | — | — | US | disclosed |
| US-20090275748-A1 | Benzoimidazole compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-11-05 | — | — | US | disclosed |
| US-20090270613-A1 | Benzoimidazole compounds | EDWARDS JAMES P | 2009-10-29 | — | — | US | disclosed |
| US-20090270611-A1 | Benzoimidazole compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-10-29 | — | — | US | disclosed |
| US-20090270366-A1 | Benzoimidazole compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-10-29 | — | — | US | disclosed |
| US-20090264646-A1 | Benzoimidazole compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-10-22 | — | — | US | disclosed |
| US-20090264645-A1 | Benzoimidazole compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-10-22 | — | — | US | disclosed |
| US-20090264647-A1 | 5-Fluoro-4-methyl-2-{2-[4-(4-methyl-piperazin-1-yl)-butoxy]-pyridin-4-yl}-1H-benzoimidazole; leukocyte recruitment inhibition, modulating H4 receptor, and treating conditions such as inflammation | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-10-22 | — | — | US | disclosed |
| US-20090247508-A1 | Benzoimidazole Compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-10-01 | — | — | US | disclosed |
| EP-1673348-B1 | BENZOIMIDAZOLE COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2009-04-01 | — | — | EP | disclosed |
| US-7432378-B2 | Benzoimidazole compounds | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-10-07 | — | — | US | disclosed |
| EP-1673348-A2 | BENZOIMIDAZOLE COMPOUNDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-06-28 | — | — | EP | disclosed |
| WO-2005044807-A2 | BENZOIMIDAZOLE COMPOUNDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-05-19 | — | — | WO | disclosed |
| US-20050070550-A1 | Benzoimidazole compounds | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270613-A1 | Benzoimidazole compounds | HRH4, HRH3, BRD4 | HRH1 5/4885CCR3 57/4885HRH3 2/4885 |
| US-20090264646-A1 | Benzoimidazole compounds | HRH4, HRH3, BRD4 | HRH1 5/4885CCR3 57/4885HRH3 2/4885 |
| US-20050070550-A1 | Benzoimidazole compounds | HRH4, HRH3, BRD4 | HRH1 5/4885CCR3 57/4885HRH3 2/4885 |
| US-20090270366-A1 | Benzoimidazole compounds | HRH4, HRH3, BRD4 | HRH1 5/4885CCR3 57/4885HRH3 2/4885 |
| US-20090270611-A1 | Benzoimidazole compounds | HRH4, HRH3, BRD4 | HRH1 5/4885CCR3 57/4885HRH3 2/4885 |
| US-20090275748-A1 | Benzoimidazole compounds | HRH4, HRH3, BRD4 | HRH1 5/4885CCR3 57/4885HRH3 2/4885 |
| US-20090264647-A1 | 5-Fluoro-4-methyl-2-{2-[4-(4-methyl-piperazin-1-yl)-butoxy]-pyridin-4-yl}-1H-benzoimidazole; leukocyte recruitment inhibition, modulating H4 receptor, and treating conditions such as inflammation | HRH4, HRH3, BRD4 | HRH1 15/4885CCR3 76/4885HRH3 2/4885 |
| US-20090247508-A1 | Benzoimidazole Compounds | HRH4, HRH3, BRD4 | HRH1 5/4885CCR3 57/4885HRH3 2/4885 |
| US-20090264645-A1 | Benzoimidazole compounds | HRH4, HRH3, BRD4 | HRH1 5/4885CCR3 57/4885HRH3 2/4885 |
| US-20090281307-A1 | Benzoimidazole compounds | HRH4, HRH3, BRD4 | HRH1 5/4885CCR3 57/4885HRH3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.